Lilly to Buy AtaiBeckley in $2.8 Billion Cash-and-CVR Deal
Eli Lilly's move for a clinical-stage psychedelics developer bets a milestone-laden contingent payout on turning a Breakthrough Therapy-designated depression drug into a marketed medicine.
Eli Lilly and Company (LLY) agreed to acquire AtaiBeckley Inc. (ATAI) in a deal valuing the clinical-stage mental health company at approximately $2.8 billion, structured as a mix of upfront cash and a contingent milestone payout.
Under the agreement, Lilly will pay $6.75 a share in cash at closing, plus up to $2.50 a share through a Contingent Value Right tied to development and regulatory milestones for AtaiBeckley's two lead programs, BPL-003 and VLS-01. The upfront cash represents the roughly $2.8 billion equity value, while the CVR carries an additional potential aggregate value of about $1.0 billion, with payouts running from a $1.00-a-share trigger on VLS-01's Phase 3 initiation to $0.50 and $1.00 tranches tied to U.S. approval and DEA rescheduling of the two drugs over the next several years. The purchase price represents a premium of approximately 40% to AtaiBeckley's 30-day volume-weighted average trading price through July 15, 2026. The deal is not subject to a financing condition and is expected to close in the third quarter, pending AtaiBeckley shareholder approval and customary regulatory clearances.
Lilly framed the acquisition as an expansion of its neuroscience pipeline into treatment-resistant depression, a condition it said persists for millions of patients despite multiple prior treatments. "Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works," said Carole Ho, executive vice president and president, Lilly Neuroscience. "Advancing AtaiBeckley's investigational therapies gives us a real chance to change that".
AtaiBeckley's lead asset, BPL-003, is an intranasal synthetic form of 5-MeO-DMT designed to restore synaptic connectivity rather than simply adjust neurotransmitter levels, the mechanism underlying conventional antidepressants. The drug has Breakthrough Therapy Designation from the FDA and has entered Phase 3 activities after a Phase 2b study showed rapid, durable symptom reduction following a single in-clinic dosing session lasting about two hours. AtaiBeckley co-founder and CEO Srinivas Rao said joining Lilly gives the pipeline "the benefit of the resources and scale Lilly has to potentially advance therapies faster than we could alone," while chairman Christian Angermayer called the deal "the best path forward for patients and shareholders".
The transaction lands roughly three months after Lilly's pending $6.3 billion cash-and-CVR acquisition of Centessa Pharmaceuticals, a deal built around Centessa's orexin portfolio for narcolepsy and idiopathic hypersomnia and carrying a similar 40.5% takeout premium. Taken together, the two deals point to Lilly using cash-plus-milestone structures to absorb clinical-stage neuroscience assets while shifting regulatory and commercial risk onto sellers through extended CVR windows.
Apeiron Investment Group and all of AtaiBeckley's directors and officers have signed voting agreements covering about 15% of outstanding shares, and the boards of both companies have approved the transaction. Goldman Sachs is advising Lilly, while Moelis & Company, Centerview Partners and Citi are advising AtaiBeckley. Lilly will determine GAAP accounting treatment upon closing, after which the deal will be reflected in its financial results and guidance.